S1 Data - by Levicatus Mugenyi (6393749)

Subjects:

Consort chart showing number of HIV patients and their six months follow up outcomes at 11 TASO health facilities in Uganda for PLHIV enrolled in care in the period 2015–2018. by Levicatus Mugenyi (6393749)

Subjects:

Parameter estimates, standard errors and p-values from the segmented regression models predicting six-month retention and mortality among PLHIV enrolled in the 11 TASO health facil... by Levicatus Mugenyi (6393749)

Subjects:

Primary and secondary outcomes of the randomized clinical trial groups at 3 months and 12 months. by Teemu P. Hevonkorpi (11577571)

Subjects:

Baseline characteristics of 291 patients by randomization group. by Teemu P. Hevonkorpi (11577571)

Subjects:

Adverse events at 12-month follow-up by study group. by Teemu P. Hevonkorpi (11577571)

Subjects:

Participant flow diagram of the DRIFT trial. by Teemu P. Hevonkorpi (11577571)

Subjects:

Between-group differences of mean PRWE with 95% confidence intervals in primarily malaligned DRFs and early malaligned DRFs at 3-month and 12-month follow-up. by Teemu P. Hevonkorpi (11577571)

Subjects:

CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i>^<i>ECKO</i> mice and lesions in the retina of <i>Ccm2</i>^<i>ECKO</i> mice. by Jia Li (160557)

D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

Chronic exposure of human PAC to nicotine decreases carrier-mediated [³H] thiamin uptake. by Padmanabhan Srinivasan (481324)

Oleic acid treatment decreases MDA formation, and induces UCP2 and AMPK in septic mice. by Cassiano Felippe Gonçalves-de-Albuquerque (846954)

Distribution of IgG antibodies to SARS-CoV-2 spike (full-length spike, S, and S1 subunit receptor binding domain, RBD) and nucleocapsid (N) in nursing home residents—Georgia, Decem... by Zeshan A. Chisty (18388200)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects: